MUC5B rs35705950 次要等位基因与特发性肺纤维化患者年龄及生存的关联
这项回顾性研究纳入8个欧洲中心1751例IPF患者,分析MUC5B rs35705950基因型与生存及临床特征的关系。多变量Cox模型显示MUC5B次要等位基因是生存的独立预测因素,携带者诊断年龄更大(p=0.001),且≥56岁携带者中位无移植生存45个月,显著优于非携带者的29个月(p=4×10-12)。
要点
- MUC5B次要等位基因是IPF生存的独立预测因素。
- 携带者诊断年龄更大,且携带比例随年龄增长而增加。
- ≥56岁携带者中位无移植生存较非携带者延长16个月。
核心结论
- 在>56岁的欧洲IPF人群中,MUC5B次要等位基因携带与中位无移植生存延长16个月相关。
研究设计与样本
- 回顾性研究,纳入来自8个欧洲中心的1751例IPF患者,分析MUC5B rs35705950基因型、人口学、诊断时临床特征及生存数据。
主要发现
- 多变量Cox比例风险模型校正年龄、性别、高分辨率CT模式、吸烟行为及肺功能后,MUC5B次要等位基因是生存的显著独立预测因素。
- MUC5B次要等位基因携带者诊断时年龄显著更大(p=0.001)。
- 携带者比例随年龄显著增加,<56岁患者中为44%,>75岁患者中为63%。
- 在<56岁IPF患者中,MUC5B次要等位基因与生存无关。
- 在≥56岁IPF患者中,携带者中位生存45个月(CI: 42-49),非携带者29个月(CI: 26-33),p=4×10-12。
临床怎么用
- MUC5B基因型状态可能有助于IPF患者临床管理中的疾病预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The minor T-allele of the MUC5B promoter polymorphism rs35705950 is strongly associated with idiopathic pulmonary fibrosis (IPF). However, conflicting results have been reported on the relationship between the MUC5B minor allele and survival and it is unknown whether a specific subgroup of IPF patients might benefit from MUC5B minor allele carriage. We investigated the association between MUC5B rs35705950, survival and patient characteristics in a real-world population of European IPF patients. METHODS: In this retrospective study, 1751 patients with IPF from 8 European centres were included. MUC5B rs35705950 genotype, demographics, clinical characteristics at diagnosis and survival data were analysed. RESULTS: In a multi-variate Cox proportional hazard model the MUC5B minor allele was a significant independent predictor of survival when adjusted for age, sex, high resolution computed tomography pattern, smoking behaviour and pulmonary function tests in IPF. MUC5B minor allele carriers were significantly older at diagnosis (p = 0.001). The percentage of MUC5B minor allele carriers increased significantly with age from 44% in patients aged <56 year, to 63% in patients aged >75. In IPF patients aged <56, the MUC5B minor allele was not associated with survival. In IPF patients aged ≥56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42-49]) compared to non-carriers (29 months [CI: 26-33]; p = 4 × 10-12 ). CONCLUSION: MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years. MUC5B genotype status might aid disease prognostication in clinical management of IPF patients.
引用
- van der Vis JJ, Prasse A, Renzoni EA, et al. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis. Respirology. 2022. PMID: 36571111. doi:10.1111/resp.14440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。